Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,192.00
Bid: 12,192.00
Ask: 12,194.00
Change: -224.00 (-1.80%)
Spread: 2.00 (0.016%)
Open: 12,234.00
High: 12,238.00
Low: 12,172.00
Prev. Close: 12,416.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2020 16:00

RNS Number : 3749L
AstraZeneca PLC
29 April 2020
 

29 April 2020 16:00 BST

 

Results of Annual General Meeting held on 29 April 2020

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019

 

1,061,180,101

99.92

872,215

0.08

1,062,052,316

80.93%

7,121,452

2

To confirm dividends

 

1,058,995,786

99.10

9,598,531

0.90

1,068,594,317

81.43%

579,469

3

To reappoint PricewaterhouseCoopers LLP as Auditor

 

1,068,300,235

99.97

312,449

0.03

1,068,612,684

81.43%

560,776

4

To authorise the Directors to agree the remuneration of the Auditor

 

1,067,398,628

99.90

1,086,858

0.10

1,068,485,486

81.42%

687,961

5a

To re-elect Leif Johansson as a Director

 

1,065,113,167

99.69

3,276,071

0.31

1,068,389,238

81.42%

784,805

5b

To re-elect Pascal Soriot as a Director

 

1,067,248,723

99.90

1,033,124

0.10

1,068,281,847

81.41%

892,364

5c

To re-elect Marc Dunoyer as a Director

 

1,060,164,242

99.25

8,056,265

0.75

1,068,220,507

81.40%

952,979

5d

To re-elect Geneviève Berger as a Director

 

882,846,920

83.06

179,994,848

16.94

1,062,841,768

80.99%

6,331,650

5e

To re-elect Philip Broadley as a Director

 

1,066,048,992

99.79

2,190,705

0.21

1,068,239,697

81.41%

933,713

5f

To re-elect Graham Chipchase as a Director

 

1,062,682,507

99.48

5,520,936

0.52

1,068,203,443

81.40%

969,967

5g

To elect Michel Demaré as a Director

 

1,066,252,259

99.82

1,969,593

0.18

1,068,221,852

81.40%

951,558

5h

To re-elect Deborah DiSanzo as a Director

 

1,067,836,362

99.97

351,091

0.03

1,068,187,453

81.40%

985,957

5i

To re-elect Sheri McCoy as a Director

 

1,064,329,862

99.64

3,890,368

0.36

1,068,220,230

81.40%

951,792

5j

To re-elect Tony Mok as a Director

1,067,117,370

99.90

1,066,669

0.10

1,068,184,039

81.40%

989,371

5k

To re-elect Nazneen Rahman as a Director

 

1,067,376,963

99.92

821,467

0.08

1,068,198,430

81.40%

973,592

5l

To re-elect Marcus Wallenberg as a Director

 

955,082,665

89.42

113,060,725

10.58

1,068,143,390

81.40%

1,030,019

6

To approve the Annual Report on Remuneration for the year ended 31 December 2019

 

1,032,308,145

96.65

35,747,783

3.35

1,068,055,928

81.39%

1,118,038

7

To approve the Directors' Remuneration Policy

 

972,774,742

94.71

54,292,376

5.29

1,027,067,118

78.27%

42,106,679

8

To authorise limited political donations

 

1,038,907,152

97.75

23,872,400

2.25

1,062,779,552

80.99%

6,394,668

9

To authorise the Directors to allot shares

 

910,654,650

85.26

157,472,093

14.74

1,068,126,743

81.40%

1,046,979

10

To authorise the Directors to disapply pre-emption rights

 

1,058,066,972

99.23

8,200,338

0.77

1,066,267,310

81.26%

2,906,339

11

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

 

1,054,711,677

98.92

11,513,414

1.08

1,066,225,091

81.25%

2,948,557

12

To authorise the Company to purchase its own shares

 

1,051,131,060

98.41

16,950,800

1.59

1,068,081,860

81.39%

1,091,896

13

To reduce the notice period for general meetings

 

998,062,805

93.44

70,101,553

6.56

1,068,164,358

81.40%

1,008,865

14

To approve the 2020 Performance Share Plan

1,010,149,491

95.66

45,877,396

4.34

1,056,026,887

80.48%

13,147,356

 

Issued capital

As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGPPURCCUPUGCB
Date   Source Headline
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer
19th Oct 20181:09 pmRNSCHMP positive opinion Bevespi Aerosphere
16th Oct 20187:00 amRNSFDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 20183:00 pmRNSTotal Voting Rights
1st Oct 20187:00 amRNSAtacand Agreement with Cheplapharm Completed
28th Sep 20184:00 pmRNSPrevious Announcement Regarding Appointment Of NED
25th Sep 20181:15 pmRNSOverall survival data for Imfinzi: Stage III NSCLC
24th Sep 20184:10 pmRNSEMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 20187:00 amRNSFarxiga gets positive result in DECLARE-TIMI 58
14th Sep 20187:00 amRNSFDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 20187:00 amRNSTezepelumab FDA Breakthrough Therapy Designation
6th Sep 20187:00 amRNSDirectorate Change
3rd Sep 20183:00 pmRNSTotal Voting Rights
31st Aug 20187:00 amRNSAstraZeneca Update on Anifrolumab in SLE
30th Aug 20187:00 amRNSEC approves Bydureon BCise device for T2 diabetes
23rd Aug 20187:00 amRNSAstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 20187:00 amRNSAZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 20187:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20187:00 amRNSEMA grants OD for selumetinib in NF1
1st Aug 20183:00 pmRNSTotal Voting Rights
27th Jul 20182:00 pmRNSCHMP recommends Imfinzi for Stage III nsclc
26th Jul 20187:00 amRNSAZN: H1 2018 Results
24th Jul 20187:00 amRNSAtacand to be divested to Cheplapharm in Europe
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 201812:00 pmRNSHolding(s) in Company
2nd Jul 20183:00 pmRNSTotal Voting Rights
2nd Jul 20187:00 amRNSImfinzi approved in Japan for Stage III nsclc
2nd Jul 20187:00 amRNSLynparza approved in Japan for BRCAm breast cancer
29th Jun 20183:00 pmRNSBydureon receives positive CHMP opinion for BCise
28th Jun 20181:30 pmRNSAZ and Luye Pharma complete agreement for Seroquel
27th Jun 20187:00 amRNSLynparza: significant PFS 1st-line ovarian cancer
26th Jun 20187:00 amRNSBoard Committee Changes
22nd Jun 20187:00 amRNSPublication of a Prospectus
12th Jun 20187:00 amRNSUpdate: lanabecestat Phase III Alzheimer's trials
8th Jun 20185:30 pmRNSEU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 20187:00 amRNSDirector Declaration
1st Jun 20183:00 pmRNSBlock listing Interim Review
1st Jun 20183:00 pmRNSTotal Voting Rights
1st Jun 201811:00 amRNSDirector Declaration
30th May 20187:00 amRNSUpdate on TERRANOVA PIII trial for Fasenra in COPD
25th May 20187:00 amRNSAZ's Imfinzi: significant OS in Stage III nsclc
21st May 20187:00 amRNSAZ regulatory submission in Japan for Forxiga
21st May 20187:00 amRNSUS FDA approves Lokelma for adult hyperkalaemia
18th May 20185:30 pmRNSResult of AGM
18th May 20187:00 amRNSAZN: Q1 2018 Results
11th May 20187:00 amRNSAstraZeneca update on Fasenra PIII trial in COPD
8th May 201811:00 amRNSEMA approves Lynparza: maintenance ovarian cancer
8th May 20187:00 amRNSAZ and Luye Pharma enter agreement for Seroquel
4th May 201812:00 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.